



FOR IMMEDIATE RELEASE

First Patient enrolled in Phase IIb Clinical Trial of Anfibatide in China

Hong Kong, October 26, 2015—Lee's Pharmaceutical Holdings Limited (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that the first patient for the phase IIb study of Anfibatide has been successfully enrolled.

This is a phase IIb multi-centers, double-blinded, paralleled group, placebo controlled clinical study (clinicaltrial.gov registration No.:NCT02495012), led by the Peking University First Hospital. The study aims to evaluate the safety, efficacy, tolerability of Anfibatide in ST-segment elevation myocardial infarction (STEMI) patients who undergo PCI treatment after coronary angiography. This proof of concept study plans to enroll a total of 240 patients and standard dual antiplatelet strategy is employed with or without Anfibatide. The study involved a total of 12 centers across China.

The first patient of this study has been enrolled on 19th October 2015 in the Xiangya Hospital of Central South University.

"We are thrilled of reaching this important milestone for Anfibatide development. This study will provide valuable information on the clinical benefit of new antiplatelet deployment on top of current standard treatment regimen for patients with acute coronary syndrome," said Dr. Benjamin Li, Chief Executive Officer of the Group. "The start of the enrollment is a major step forward towards our goal to bring new and paradigm shifting medicine to patients."

About Anfibatide

Anfibatide is a new molecular entity discovered and developed by the Group. It is a first-in-class platelet 1b receptors antagonist and is currently undergone phase II clinical study. Animal studies have shown that intravenous injection of Anfibatide effectively abolishes the cyclic flow reduction in canine model of unstable angina with much less prolongation of bleeding time than platelet 2b3a receptors antagonist. Phase I study reveals that Anfibatide is a potent inhibitor of platelet aggregation in healthy volunteer and does not increase the risk of bleeding. Anfibatide represents a novel therapeutic mechanism and may advance the treatment of acute coronary syndrome and percutaneous coronary intervention. It is expected that Anfibatide could have an important role in preventing thrombosis and plaque progression at sites of pathological endothelial injury, contributing to the treatment of unstable angina as well as to reduction of thrombosis in patients undergone PTCA and stenting. The Group has obtained patents in US and China for this product.



FOR IMMEDIATE RELEASE

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based biopharmaceutical company listed in Hong Kong with more than 20 years of operation in China's pharmaceutical industry. It is fully integrated with a strong infrastructure in drug development, manufacturing, sales and marketing. It has established extensive partnerships with more than 20 international companies and currently has 14 products in the market place. Lee's Pharmaceutical focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. The company's development program is lauded with 30 product candidates stemming from both internal R&D efforts and collaborations with US, European and Japanese companies, including promising compounds to treat liver cancer and pulmonary hypertension. The mission of Lee's Pharmaceutical is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information is available at <http://www.leespharm.com>.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com